VCAM-1 Is Upregulated in Uranium Miners Compared to Other Miners

Nour A. Ass’ad 1, Xin Shore 2, Orrin Myers 2, Alexandra R. Camacho 3, Quiteria Jacquez 3, Charles Pollard 4, Linda S. Cook 1,5, Shuguang Leng 1, Kimberly Page 1, Akshay Sood 1,4,5 and Katherine E. Zychowski 3,*,1

1 Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; nassad@salud.unm.edu (N.A.A.); lcook@salud.unm.edu (L.S.C.); SLeng@salud.unm.edu (S.L.); pagek@salud.unm.edu (K.P.); ASood@salud.unm.edu (A.S.)
2 Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; xinwang1@salud.unm.edu (X.S.); Omyers@salud.unm.edu (O.M.)
3 College of Nursing, University of New Mexico-Health Sciences Center, Albuquerque, NM 87131, USA; ARCamacho@salud.unm.edu (A.R.C.); qsanchez@salud.unm.edu (Q.J.)
4 Miners’ Colfax Medical Center, 203 Hospital Drive, Raton, NM 87740, USA; cpollard@minershosp.com
5 Department of Epidemiology, School of Public Health, University of Colorado-Anschutz, Aurora, CO 80045, USA
* Correspondence: kzychowski@salud.unm.edu

Abstract: The United States has a rich history of mining including uranium (U)-mining, coal mining, and other metal mining. Cardiovascular diseases (CVD) are largely understudied in miners and recent literature suggests that when compared to non-U miners, U-miners are more likely to report CVD. However, the molecular basis for this phenomenon is currently unknown. In this pilot study, a New Mexico (NM)-based occupational cohort of current and former miners (n = 44) were recruited via a mobile screening clinic for miners. Serum- and endothelial-based endpoints were used to assess circulating inflammatory potential relevant to CVD. Non-U miners reported significantly fewer pack years of smoking than U-miners. Circulating biomarkers of interest revealed that U-miners had significantly greater serum amyloid A (SAA), soluble intercellular adhesion molecule 1 (ICAM-1, ng/mL), soluble vascular cell adhesion molecule 1 (VCAM-1, ng/mL), and VCAM-1 mRNA expression, as determined by the serum cumulative inflammatory potential (SCIP) assay, an endothelial-based assay. Even after adjusting for various covariates, including age, multivariable analysis determined that U-miners had significantly upregulated VCAM-1 mRNA. In conclusion, VCAM-1 may be an important biomarker and possible contributor of CVD in U-miners. Further research to explore this mechanism may be warranted.

Keywords: VCAM-1; inflammation; cardiovascular; mining

1. Introduction

Mining demonstrates significant risks for long-term health effects. Chronic health conditions such as lung diseases [1–3] and to a lesser extent, cardiovascular diseases (CVD), may impact uranium (U) miners [4–6]. The Southwestern U.S. has a rich culture of mining, including coal, U, and other metals. The majority of U-mines cumulatively produced more than 225 million tons of ore between 1949–1989 [7], with some current active U-mining in the western states. Mining and affiliated professions such as processing and transporting U-ore have been investigated with respect to CVD, but results are conflicting. Recently, U-miners exhibited an increase in self-reported angina compared to non-U miners, despite having lower body mass index (BMI), lower nicotine use, and lower duration of mining tenure than non-U miners [8]. In a study of French U-miners, CVD death rates were higher among U-miners, with a significantly higher risk of cerebrovascular mortality [9,10]. In contrast, other cohort studies have determined no evidence in U-miner mortality from
CVD [4]. In a French U-miners’ cohort, authors observed that specific exposure to soluble, reprocessed U may increase CVD mortality [11].

Endothelial dysfunction is considered to be a sentinel physiological indicator of subsequent CVD [12]. Endothelial cells express adhesion molecules upon systemic insult and VCAM-1 is an endothelial adhesion molecule, upregulated upon cellular activation [13]. VCAM-1 and other markers may be predictive of CVD risk in both men and women [14]. This adhesion molecule promotes binding to circulating leukocytes via very late antigen-4 (VLA-4), and promotes leucocyte adhesion and transendothelial migration, which subsequently contribute to atherosclerotic plaque development [15]. Our lab and others have demonstrated that endothelial responses to patient serum can be used to assess circulating inflammatory potential, relevant to CVD, even in the presence or absence of canonical inflammatory biomarkers, such as cytokines [16–18]. This novel endothelial bioassay, the ‘serum cumulative inflammatory potential assay’ (SCIP assay), has pinpointed circulating factors as drivers of CVD, especially following inhaled exposures or other lung injury-inducing diseases. Other inflammatory markers such as interleukins (such as IL-8) and serum amyloid A (SAA) have also demonstrated a role in driving CVD. For example, one study found that SAA was a predictor of coronary artery disease (CAD) and CVD in women [19]. Another study determined the IL-8 signaling directly augments endothelial cell survival, proliferation, and matrix metalloproteinase production via regulation of angiogenic pathways [20].

The aim of this pilot clinical study was to assess molecular biomarkers of CVD, including implementing a novel endothelial bioassay [21,22], in a cohort of miners. We postulated that U-miners would exhibit a significantly more inflammatory and pathological phenotype than non-U miners, based on circulating molecular and endothelial endpoints. To our knowledge, this is the first assessment of molecular CVD biomarkers in a mining occupational cohort. This inaugural study is of critical importance to understanding occupational exposures in hazardous industries, such as mining, and long-term health outcomes.

2. Materials and Methods

2.1. Patient Recruitment and Biospecimen Collection

This cross-sectional study was a joint project between Miners’ Colfax Medical Center (MCMC) and the University of New Mexico Health Sciences Center. All patient subjects were recruited from the MCMC mobile outreach. The MCMC mobile screening clinic is held once a month at rural locales including Questa, Farmington, and Alamogordo, NM, USA (Figure 1). This screening clinic consists of a 53 ft long platform with a generator for the power supply. Outreach clinics were advertised to communities via print, media, radio, as well as through community/church leaders, in addition to self-referral. Patients completed a screening survey, underwent a routine physical exam, and were assessed for respiratory symptoms of disease. Patients completed a clinical health survey to address CVD endpoints including self-reported medical history. Blood was drawn immediately following the clinical visit and extracted serum was flash frozen for further analyses through the UNM Molecular Epidemiology Laboratory. Risk factors for CVD, assessed at the time of examination included age, sex, race/ethnicity, body mass index, smoking status, self-reported hypertension, measured systolic or diastolic hypertension, and medication history. In addition, a basic blood panel including total cholesterol, HDL, LDL, triglyceride levels and markers of insulin resistance including hemoglobin A1c (HbA1c), non-fasting glucose, and insulin levels were evaluated in each participant. A total of 44 patient subjects were recruited for the purposes of this study (10 U-miners and 34 non-U miners).
Figure 1. A rural mobile screening clinic through Miners’ Colfax Medical Center was held in Questa, Alamogordo, and Farmington, NM, periodically to recruit 44 patient participants.

2.2. Inclusion Criteria and Mining Status

Recruited subjects were required to be employed in the mining industry at least 1 year and all participants provided total years of mining tenure. Exposure status was defined as those who were ever employed in the U-mining industry (U-miners) vs. those who mined other ores including coal, metal, and non-metals (non-U miners).

2.3. Serum Cumulative Inflammatory Potential (SCIP) Assay

Human coronary artery endothelial cells (hCAECs, Lonza) were grown in confluence T75 sterile flasks (hCAECs, Lonza). Basal complete media were replaced every other day and cells were passaged once per week. Human coronary artery endothelial cells were seeded in a 24-well plate and grown to confluence in complete media. For the 44 deidentified patient serum samples (with no name, medical record number, or birthday), 25 µL serum in 475 µL of serum-free commercial media, 5% serum by volume per well, were incubated with a confluent hCAEC monolayer. Samples were incubated at 37 °C for 4 h. Total RNA was extracted from cells using a commercially-available kit (RNeasy, Qiagen, Germantown, Maryland) based on the manufacturer’s instructions. The extracted RNA was then aliquoted in cryosafe centrifuge tubes and frozen at −80 °C. RNA was then thawed and reverse transcribed using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, CA, USA), prior to qPCR. Using the Taqman Gene Expression protocol, gene expression was assessed including VCAM-1 (Hs01003372_m1), ICAM-1 (Hs01003372_m1), and chemokine ligand-2 (CCL-2, Hs00234140_m1), as per the manufacturer’s instructions (ThermoScientific, Waltham, MA, USA). Target genes were normalized to TATA binding protein (TBP, Hs99999910_m1). Relative gene expression using endothelial targets were analyzed using the $2^{-\Delta\Delta CT}$ method, as previously described [23]. Endothelial transcriptional responses to serum was evaluated using qPCR. Genes evaluated included chemokine ligand 2 (CCL-2), ICAM-1, and VCAM-1.
2.4. Serum Cytokine Analysis

The V-PLEX vascular injury panel 2 (human) kit (Mesoscale Discovery, Rockville, MD, USA) measures 4 serum-borne biomarkers, critical to acute inflammation and tissue damage in vascular disease. This is an electrochemiluminescence (ECL) detection technique that differs somewhat from traditional colormetric, antibody-based ELISAs. These included serum amyloid A (SAA), C-reactive protein (CRP), VCAM-1, and ICAM-1. This protocol was performed using the appropriate serum volume per biological sample, according to the manufacturers’ instructions. Additional circulating cytokines assessed included interferon gamma (IFN-γ), interleukin-10 (IL-10), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-α).

2.5. Statistical Analysis

We tested whether exposure to uranium mining was associated with differences in inflammation biomarker levels and with other miner characteristics. Inflammation biomarkers are described above, and miner characteristics included gender, diabetes, age, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) cholesterol, low density lipoprotein (LDL), years of mining (mining tenure), pack years, HbA1c, statins, insulin, and glucose. Unadjusted associations between uranium miner status and continuous variables were tested using Student’s t-tests and non-parametric Wilcoxon tests. Multivariable linear model variable selection analyses were conducted for each inflammation biomarker with uranium miner status forced into the model and adding other potential confounders as covariates. Due to the small sample size, no more than 2 additional parameters were added into models. Dependent variables were log-transformed before analyses. Fit of models was summarized using the adjusted coefficient of determination (R-squared) and Akaike’s Information Criteria corrected for small samples (AICC). For AICC, smaller values indicate a more favorable tradeoff between the number of parameters and fit, and models that differ by less than 2.0 AICC units (ΔAICC ≤ 2) are essentially equivalent models [24]. Data were analyzed using Statistical Analysis Software 9.4 (SAS Institute Inc., Cary, NC, USA, 2020).

3. Results

3.1. Demographics and Baseline Health Metrics

Demographic and patient characteristics relevant to CVD are presented in Table 1 between U and non-U miners. The majority of participants were male (80%), similar to previous studies of miners [8,25]. The majority of participants were Hispanic (61%), followed by White (25%) and American Indian (14%) (Table 1). Uranium miners were significantly older than non-U miners (p = 0.04) and had significantly more pack years of smoking (p < 0.01) (Table 2). Furthermore, U-miners weighed significantly more than non-U miners (p = 0.02); however, BMI did not demonstrate any significant difference. Measured blood pressure (diastolic, systolic, mean arterial), mining tenure, cholesterol, HDL, LDL, triglycerides, HbA1c, glucose, and insulin did not significantly differ between U-miners and non-U miners.

| Table 1. Characteristics of study participants. |
|-----------------------------------------------|
|                                               |
| All (n = 44)                                   |
| Non-U Miners (n = 34)                          |
| U-Miners (n = 10)                              |
|                                               |
| Gender                                        |
| Male                                          |
| 42 (95)                                       |
| 34 (100)                                      |
| 8 (80)                                        |
| Female                                        |
| 2 (5)                                         |
| 0                                             |
| 2 (20)                                        |
| Ethnicity                                     |
| White                                         |
| 11 (25)                                       |
| 9 (26)                                        |
| 2 (20)                                        |
| Hispanic                                      |
| 27 (61)                                       |
| 19 (56)                                       |
| 8 (80)                                        |
|                                | All (n = 44) | Non-U Miners (n = 34) | U-Miners (n = 10) |
|--------------------------------|--------------|-----------------------|------------------|
| **American Indian**            |              |                       |                  |
| Yes                            | 6 (14)       | 6 (18)                | 0                |
| No                             | 39 (89)      | 30 (88)               | 9 (90)           |
| **Current Smoker**             |              |                       |                  |
| Yes                            | 5 (11)       | 4 (12)                | 1 (10)           |
| No                             | 39 (89)      | 30 (88)               | 9 (90)           |
| **Diabetic**                   |              |                       |                  |
| Yes                            | 8 (18)       | 4 (12)                | 4 (40)           |
| No                             | 36 (82)      | 30 (88)               | 6 (60)           |
| **Hypertensive**               |              |                       |                  |
| Yes                            | 16 (36)      | 13 (38)               | 3 (30)           |
| No                             | 28 (64)      | 21 (62)               | 7 (70)           |
| **High Cholesterol**           |              |                       |                  |
| Yes                            | 10 (23)      | 8 (24)                | 2 (20)           |
| No                             | 34 (77)      | 26 (76)               | 8 (80)           |
| **Coronary artery disease**    |              |                       |                  |
| Yes                            | 44 (100)     | 34 (100)              | 10 (100)         |
| No                             |              |                       |                  |
| **Statin usage**               |              |                       |                  |
| Yes                            | 7 (16)       | 5 (15)                | 2 (20)           |
| No                             | 28 (64)      | 20 (59)               | 8 (80)           |
| Unknown                        | 9 (20)       | 9 (26)                | 0                |
| **HDL Value**                  |              |                       |                  |
| HDL < 40                       | 17 (39)      | 15 (44)               | 2 (20)           |
| HDL 40+                        | 27 (61)      | 19 (56)               | 8 (80)           |
| **LDL Value**                  |              |                       |                  |
| No data                        | 1 (2)        | 0                     | 1 (10)           |
| LDL ≤ 100                      | 30 (68)      | 23 (68)               | 7 (70)           |
| LDL > 100                      | 13 (30)      | 11 (32)               | 2 (20)           |
| **Triglycerides Value**        |              |                       |                  |
| Trig < 150                     | 21 (48)      | 16 (47)               | 5 (50)           |
| Trig 150+                      | 23 (52)      | 18 (53)               | 5 (50)           |
| **Glucose**                    |              |                       |                  |
| 60–139 gm/dL: normal           | 40 (91)      | 30 (88)               | 10 (100)         |
| 140–199 mg/dL: at risk         | 2 (5)        | 2 (6)                 | 0                |
| 200+ mg/dL                     | 2 (5)        | 2 (6)                 | 0                |
Table 1. Cont.

|                      | All (n = 44) | Non-U Miners (n = 34) | U-Miners (n = 10) |
|----------------------|-------------|-----------------------|------------------|
| **HbA1c**            |             |                       |                  |
| HbA1c ≤ 7            | 38 (86)     | 29 (85)               | 9 (90)           |
| HbA1c > 7            | 6 (14)      | 5 (15)                | 1 (10)           |
| **Body Mass Index**  |             |                       |                  |
| BMI < 25             | 6 (14)      | 4 (12)                | 2 (20)           |
| BMI ≥ 25             | 38 (86)     | 30 (88)               | 8 (80)           |

Table 2. Characteristics of study participants based on mining type.

|                          | Non-U Miners | U-Miners | p-Value a |
|--------------------------|--------------|----------|-----------|
|                          | Mean         | Std      | Mean      | Std      |           |
| Age                      | 55.9         | 16.2     | 66.9      | 6.2      | 0.04      |
| Pack-years               | 7.5          | 11.3     | 24.3      | 16.7     | <0.01     |
| Years of mining exposure | 20.0         | 13.9     | 16.8      | 13.6     | 0.63      |
| Years of uranium exposure| 0            | 0        | 4.4       | 3.9      | N/A       |
| BMI                      | 32.1         | 6.8      | 27.5      | 4.3      | 0.07      |
| Systolic Blood Pressure  | 131.6        | 18.1     | 133.4     | 18.2     | 0.68      |
| Diastolic Blood Pressure | 80.7         | 7.7      | 84.0      | 6.6      | 0.15      |
| Mean Arterial Pressure, mm Hg | 97.7     | 10.3     | 100.4     | 10.3     | 0.43      |
| Cholesterol Value        | 161.5        | 35.6     | 151.3     | 39.0     | 0.50      |
| HDL Value                | 41.6         | 9.4      | 48.3      | 14.4     | 0.10      |
| LDL Value                | 86.7         | 35.6     | 77.8      | 39.2     | 0.54      |
| Triglycerides Value      | 190.6        | 116.3    | 182.3     | 133.0    | 0.57      |
| HbA1c                    | 6.4          | 2.0      | 6.0       | 1.0      | 0.99      |
| Glucose                  | 111.4        | 67.3     | 101.9     | 18.3     | 0.57      |
| Insulin                  | 29.3         | 31.3     | 35.9      | 64.3     | 0.54      |

a Nonparametric Wilcoxon Rank Sum Test.

3.2. Continuous Molecular Biomarkers

Univariate analysis indicated several detected biomarkers of CVD were upregulated in U-miners, compared to non-U miners including serum amyloid A (SAA) (p = 0.049), soluble ICAM-1 (p = 0.04), VCAM-1 (p = 0.03), IL-8 (p = 0.01), and VCAM-1 as measured in the SCIP assay (p < 0.01) (Table 3).
Table 3. Comparison of Circulating Inflammatory Molecular Biomarkers and Inflammatory Potential.

|                      | Non-U Miners | U-Miners | \(p\)-Value \(a\) |
|----------------------|--------------|----------|-------------------|
|                      | Mean         | Std      | Mean              | Std          |        |
| CRP (ng/mL)          | 3085         | 3287     | 6428              | 7002         | 0.14   |
| SAA (ng/mL)          | 2606         | 3234     | 11193             | 22179        | 0.049  |
| soluble ICAM-1 (ng/mL) | 359.9      | 93.3     | 449.2             | 128.0        | 0.04   |
| soluble VCAM-1 (ng/mL) | 377.9       | 115.1    | 540.3             | 246.6        | 0.03   |
| IFN-\(\gamma\) (pg/mL) | 6.91        | 4.36     | 8.74              | 3.79         | 0.11   |
| IL-10 (pg/mL)        | 0.31         | 0.12     | 0.34              | 0.15         | 0.61   |
| IL-6 (pg/mL)         | 2.30         | 3.00     | 3.30              | 4.20         | 0.42   |
| IL-8 (pg/mL)         | 19.80        | 8.67     | 31.14             | 15.27        | 0.01   |
| TNF-\(\alpha\) (pg/mL) | 4.10        | 1.17     | 4.57              | 0.82         | 0.30   |
| SCIP assay-CCL-2 mRNA expression | 1.00 | 0.51 | 1.21 | 0.62 | 0.27 |
| SCIP assay-VCAM-1 mRNA expression | 1.00 | 0.68 | 1.75 | 0.68 | <0.01 |
| SCIP assay-ICAM-1 mRNA expression | 1.00 | 0.22 | 1.04 | 0.15 | 0.39 |

\(a\) Nonparametric Wilcoxon Rank Sum Test.

3.3. Multivariable Models

Multivariable models, adjusted for individual covariates revealed several significantly upregulated continuous molecular biomarkers (Table 4). The VCAM-1 mRNA (SCIP assay) indicated significant association with U-mining status, even when adjusting for age and hdl (adjusted \(R^2 = 0.29, p = 0.034\)), the model with the smallest AICC, \(\Delta\text{AICC} = 0\). Models that adjusted only for age and for diabetes plus age had less support based on \(\Delta\text{AICC}\) with the latter model also having a weaker association between U-mining status and VCAM-1. The U-mining coefficient for the diabetes plus hdl model was 0.05 units lower then best-fitting model and was not different from zero (\(p = 0.088\)). Serum amyloid A (SAA, ng/mL), IL-8 (pg/mL), and soluble VCAM-1 (ng/mL) also demonstrated significant association in the U-miners group, even when adjusting for covariates (Table 4). For these biomarkers and models with \(\Delta\text{AICC} < 2.0\), there is little evidence of substantial confounding of the U-mining status association. Other tested biomarkers did not demonstrate statistical significance using either univariate or multivariable modeling.

Table 4. Multivariable linear models for association between inflammation biomarkers and U-mining status.

| Inflammation Biomarker | Model Covariates   | U-Mining \(\beta\) Coefficient Estimate | Standard Error | \(p\)-Value | Model Adjusted R-Squared | \(\Delta\text{AICC}\) |
|------------------------|--------------------|----------------------------------------|----------------|-------------|--------------------------|-------------------|
| VCAM-1 mRNA (SCIP assay) | U-mining+age      | 0.33                                   | 0.14           | 0.015       | 0.26                     | 0.43              |
|                        | U-mining+diabetes  | 0.39                                   | 0.15           | 0.007       | 0.17                     | 5.56              |
|                        | U-mining+hdl       | 0.36                                   | 0.14           | 0.010       | 0.23                     | 2.13              |
|                        | U-mining+pack years | 0.29                                  | 0.14           | 0.014       | 0.24                     | 2.85              |
|                        | U-mining+age+hdl    | 0.34                                   | 0.14           | 0.088       | 0.28                     | 0.69              |
### Table 4. Cont.

| Inflammation Biomarker | Model Covariates                          | U-Mining β Coefficient Estimate | Standard Error | p-Value | Model Adjusted R-Squared | ΔAICC |
|------------------------|-------------------------------------------|---------------------------------|----------------|---------|--------------------------|-------|
| SAA (ng/mL)            | U-mining+systolic blood pressure          | 0.91                            | 0.38           | 0.016   | 0.15                     | 0.00  |
|                        | U-mining+mean arterial pressure           | 0.87                            | 0.38           | 0.022   | 0.13                     | 0.77  |
|                        | U-mining+pack years                      | 1.21                            | 0.43           | 0.005   | 0.13                     | 1.33  |
|                        | U-mining+pack years+hdl                  | 1.21                            | 0.44           | 0.012   | 0.11                     | 3.33  |
|                        | U-mining+pack years+systolic blood pressure | 1.20                         | 0.17           | 0.004   | 0.17                     | 0.45  |
| VCAM-1 (ng/mL)         | U-mining+age                             | 0.29                            | 0.12           | 0.014   | 0.13                     | 2.89  |
|                        | U-mining+pack years                      | 0.29                            | 0.13           | 0.026   | 0.13                     | 3.11  |
|                        | U-mining+hba1c                           | 0.33                            | 0.11           | 0.003   | 0.18                     | 0.70  |
|                        | U-mining+statin usage                    | 0.26                            | 0.11           | 0.021   | 0.19                     | 0.00  |
|                        | U-mining+statin usage+hba1c              | 0.28                            | 0.11           | 0.010   | 0.22                     | 0.04  |
| IL-8 (pg/mL)           | U-mining+diastolic blood pressure        | 0.40                            | 0.15           | 0.008   | 0.15                     | 2.04  |
|                        | U-mining+mean arterial pressure           | 0.41                            | 0.15           | 0.006   | 0.14                     | 2.10  |
|                        | U-mining+cholesterol                     | 0.40                            | 0.14           | 0.005   | 0.19                     | 0.00  |
|                        | U-mining+cholesterol+diastolic blood pressure | 0.37                      | 0.15           | 0.011   | 0.18                     | 1.97  |

### 4. Discussion

#### 4.1. Key Features of These Findings

This cross-sectional study indicates that U-mining is associated with upregulation of soluble VCAM-1 and VCAM-1 mRNA expression, as measured by the SCIP assay, even after adjusting for individual, confounding covariates such as age, diabetes, HbA1c, or statin usage. U and other metals’ exposure are key contributors to the development of chronic vascular diseases and vascular events [26,27]. In this pilot study, we found that U-miners exhibited both upregulated cell adhesion molecules such as ICAM-1 and VCAM-1, which mediate leukocyte recruitment into organs following radiation exposure [28].

Upregulation of these individual adhesion molecules has been implicated in both endothelial dysfunction and increased risk of CVD [29]. Studies have found that SAA and IL-8 have also been implicated in the development of atherosclerosis [30,31]. There is conflicting literature regarding the association between CVD risk and radon or external gamma radiation exposure [32], which may suggest that other mechanisms such as mixed-metals’ exposure as the culprit driving CVD in miners. Other studies have noted an increase in inflammatory potential, as measured by the SCIP assay in Navajo residents living in close proximity to abandoned U-mines [17,26]. Our approach of using a novel, remote clinical screening platform to assess molecular biomarkers linked with CVD ultimately demonstrates the utility of remote screening to evaluate CVD risk. Future studies may focus on basic inflammatory mechanisms that may be driving upregulation of these biomarkers.

#### 4.2. Strengths of This Study

Strengths of this study include the study population that represents underserved, minority populations including White, Native American, and Hispanic miners. The mobile, rural recruitment strategy also allowed for broader geographic inclusion, including reaching individuals who are less likely to attend a hospital-based, fixed clinic. In addition, assessment of molecular biomarkers in an at-risk, occupational cohort is novel
and important to understanding possible molecular targets relevant to occupational and toxicological exposures.

4.3. Potential Limitations

The major limitation of this study was the small sample size, which decreases statistical power and increases uncertainty in selecting the best model. We are aware that these results should be repeated with a greater number for both U and non-U miners, and ongoing studies are in the process of recruiting more patients from multiple sites. Future studies will include miners recruited from both MCMC mobile outreach and the UNM-H Pulmonology Clinic. Additionally, U-mining tenure (years of U-mining) was based on self-report and therefore subjected to recall bias. Furthermore, although the SCIP assay is sensitive, detecting endothelial dysfunction in lieu of canonical cytokine changes, it is not necessarily specific to occupational exposures. However, given the preliminary and pilot nature of this study, the data collected from our study are immensely valuable.

5. Conclusions

These findings suggest that U-miners may be at higher risk for CVD, based on their molecular biomarkers and that the SCIP assay may serve as a novel way to assess circulating inflammatory potential following occupational exposures in the mining industry. Further research is warranted to decipher specific circulating, serum-borne factors that may play a role in occupational disease.

Author Contributions: Conceptualization, A.S. and K.E.Z.; Data curation, A.R.C., Q.I., A.S. and K.E.Z.; Formal analysis, X.S., O.M., L.S.C. and S.L.; Funding acquisition, K.E.Z., A.S. and N.A.A.; Investigation, A.R.C., Q.J. and K.E.Z.; Project administration, N.A.A., C.P. and A.S.; Resources, K.P. and A.S.; Writing—original draft, N.A.A. and K.E.Z.; Writing—review and editing, L.S.C. and K.P. All authors have read and agreed to the published version of the manuscript.

Funding: This grant was funded by the UNM Clinical and Translational Center pilot grant award NIH/NCATS UL1TR001449 in addition to several other sources of funding: NIH/NIEHS R00 ES029104, R21 ES032432, and HRSA H37RH00057.

Institutional Review Board Statement: This study was approved by the University of New Mexico’s Human Research Protection Office Institutional Review Board (HRPO 14-058). All patients were appropriately consented to participate in this study.

Informed Consent Statement: All patient participants were appropriately consented based on the criteria described in the approved IRB.

Data Availability Statement: Data presented in this study are available upon request from the corresponding author.

Acknowledgments: The authors would like to thank Kirsten White for technical assistance and usage of the Molecular Epidemiology Laboratory, courtesy of the Page Laboratory (UNM, Dept. of Internal Medicine).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hornung, R.W.; Meinhardt, T.J. Quantitative Risk Assessment of Lung Cancer in U.S. Uranium Miners. Heal. Phys. 1987, 52, 417–430. [CrossRef]
2. Grosche, B.; Kreuzer, M.; Kreisheimer, M.; Schnelzer, M.; Tschense, A. Lung cancer risk among German male uranium miners: A cohort study, 1946–1998. Br. J. Cancer 2006, 95, 1280–1287. [CrossRef]
3. Hoffmann, S.; Rage, E.; Laurier, D.; Laroche, P.; Guilhaumeau, C.; Ancialet, S. Accounting for Berkson and Classical Measurement Error in Radon Exposure Using a Bayesian Structural Approach in the Analysis of Lung Cancer Mortality in the French Cohort of Uranium Miners. Radiat. Res. 2017, 187, 196–209. [CrossRef] [PubMed]
4. Kreuzer, M.; Grosche, B.; Schnelzer, M.; Tschense, A.; Dufey, E.; Walsh, L. Radon and risk of death from cancer and cardiovascular diseases in the German uranium miners cohort study: Follow-up 1946–2003. Radiat. Environ. Biophys. 2010, 49, 177–185. [CrossRef]
5. Semenova, Y.; Pivina, L.; Zhuinussoy, Y.; Zhanaspayev, M.; Chirumbolo, S.; Muzdabayeva, Z.; Björklund, G. Radiation-related health hazards to uranium miners. *Environ. Sci. Pollut. Res.* 2020, 27, 34808–34822. [CrossRef] [PubMed]

6. Kraeuser, M.; Dufey, P.; Sogli, M.; Schneiher, M.; Walsh, L. External gamma radiation and mortality from cardiovascular diseases in the German WISMUT uranium miners cohort study, 1946–2008. *Radiat. Environ. Biophys.* 2013, 52, 37–46. [CrossRef]

7. Dawson, S.E.; Madsen, G.E. Psychosocial and health impacts of uranium mining and milling on navajo lands. *Health. Psychol.* 2011, 101, 618–625. [CrossRef]

8. Al Rashida, V.J.M.; Wang, X.; Myers, O.; Boyce, T.W.; Kochett, E.; Moreno, M.; Karr, R.; Ass’ad, N.; Cook, L.S.; Sood, A. Greater Odds for Angina in Uranium Miners than Non-uranium Miners in New Mexico. *J. Occup. Environ. Med.* 2018, 61, 1–7. [CrossRef]

9. Rage, E.; Caër-Lorho, S.; Drubay, D.; Ancelot, S.; Laroche, P.; Laurier, D. Mortality analyses in the updated French cohort of uranium miners (1946–2007). *Int. Arch. Occup. Environ. Heal.* 2015, 88, 717–730. [CrossRef]

10. Drubay, D.; Caër-Lorho, S.; Laroche, P.; Laurier, D.; Rage, E. Mortality from Circulatory System Diseases among French Uranium Miners: A Nested Case-Control Study. *Radiat. Res.* 2015, 183, 550–562. [CrossRef] [PubMed]

11. Canu, I.G.; Garsi, J.-P.; Caër-Lorho, S.; Jacob, S.; Collomb, P.; Acker, A.; Laurier, D. Does uranium induce circulatory diseases? First results from a French cohort of uranium workers. *Occup. Environ. Med.* 2012, 69, 404–409. [CrossRef]

12. Jourde-Chiche, N.; Fakhouri, F.; Dou, L.; Bellien, J.; Burtey, S.; Frimat, P.-A.; Kaplanski, G.; Le Quintrec, M.; Perin, V.; et al. Endothelium structure and function in kidney health and disease. *Nat. Rev. Nephrol.* 2019, 15, 87–108. [CrossRef] [PubMed]

13. Videm, V.; Albringseten, M. Soluble ICAM-1 and VCAM-1 as Markers of Endothelial Activation. *Scand. J. Immunol.* 2008, 67, 523–531. [CrossRef]

14. Deemerth, E.; Towne, B.; Blangero, J.; Siervogel, R.M. The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors and sex in humans. *Ann. Hum. Biol.* 2001, 28, 664–678. [CrossRef]

15. Thayse, K.; Kindt, N.; Laurent, S.; Carlier, S. VCAM-1 Target in Non-Invasive Imaging for the Detection of Atherosclerotic Plaques. *Biology* 2020, 9, 368. [CrossRef] [PubMed]

16. Sanchez, B.; Zhou, X.; Gardiner, A.S.; Herbert, G.; Lucas, S.; Morishita, M.; Wagner, J.G.; Lewandowski, R.; Harkema, J.R.; Shuey, C.; et al. Serum-borne factors alter cerebrovascular endothelial microRNA expression following particulate matter exposure near an abandoned uranium mine on the Navajo Nation. *Part. Fibre Toxicol.* 2020, 17, 1–14. [CrossRef] [PubMed]

17. Harmon, M.; Lewis, J.; Miller, C.; Hoover, J.; Ali, A.-M.S.; Shuey, C.; Cajero, M.; Lucas, S.; Zychowski, K.; Pacheco, B.; et al. Residential proximity to abandoned uranium mines and serum inflammatory potential in chronically exposed Navajo communities. *J. Exp. Sci. Environ. Epidemiol.* 2017, 27, 365–371. [CrossRef] [PubMed]

18. Aragon, M.; Erdely, A.; Bishop, L.; Salmen, R.; Weaver, J.; Liu, J.; Hall, P.; Eve, T.; Kodali, V.; Zeidler-Erdely, P.; et al. MMP-9-Dependent Serum-Borne Bioactivity Caused by Multiwalled Carbon Nanotube Exposure Induces Vascular Dysfunction via the CD36 Scavenger Receptor. *Toxicol. Sci.* 2016, 150, 488–498. [CrossRef]

19. Johnson, B.D. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 2004, 109, 726–732. [CrossRef] [PubMed]

20. Li, A.; Dubey, S.; Varney, M.L.; Dave, B.J.; Singh, R.K. IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis. *J. Immunol.* 2003, 170, 3369–3376. [CrossRef]

21. Zychowski, K.E.; Sanchez, B.; Pedrosa, R.P.; Lorenzi-Filho, G.; Drager, L.F.; Polotsky, V.Y.; Campen, M.J. Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells. *Atherosclerosis* 2016, 254, 59–66. [CrossRef] [PubMed]

22. Cung, H.; Aragon, M.J.; Zychowski, K.; Anderson, J.R.; Nawarskas, J.; Roldan, C.; Sood, A.; Qualls, C.; Campen, M.J. Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients. *J. Transl. Med.* 2015, 13, 1–12. [CrossRef] [PubMed]

23. Livak, K.J.; Schnittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001, 25, 402–408. [CrossRef] [PubMed]

24. Burnham, K.P.; Anderson, D.R. *A Practical Information-Theoretic Approach. Model. Selection and Multimodel Inference*; Springer: New York, NY, USA, 2002; Volume 2.

25. Assaf, N.; Sen, P.; Shore, X.; Myers, O.; Armstrong, E.; Cook, L.S.; Sood, A. New Mexico Female Miners Have Lower Odds for COPD than Their Male Counterparts. *COPD: J. Chronic Obstr. Pulm. Dis.* 2017, 19, 509–514. [CrossRef]

26. Harmon, M.; Lewis, J.; Miller, C.; Hoover, J.; Ali, A.-M.S.; Shuey, C.; Cajero, M.; Lucas, S.; Pacheco, B.; Erdei, E.; et al. Arsenic association with circulating oxidized low-density lipoprotein in a Native American community. *J. Toxicol. Environ. Heal. Part A* 2018, 81, 535–548. [CrossRef] [PubMed]

27. Zychowski, K.E.; Wheeler, A.; Sanchez, B.; Harmon, M.; Tyler, C.R.S.; Herbert, G.; Lucas, S.N.; Ali, A.-M.; Avasarala, S.; Kunda, N.; et al. Toxic Effects of Particulate Matter Derived from Dust Samples Near the Dzhidinski Ore Processing Mill, Eastern Siberia, Russia. *Cardiovasc. Toxicol.* 2019, 19, 401–411. [CrossRef] [PubMed]

28. Mollá, M.; Gironella, M.; Miquel, R.; Tovar, V.; Engel, P.; Biete, A.; Piquè, J.; Panés, J. Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. *Int. J. Radiat. Oncol.* 2003, 57, 264–273. [CrossRef]

29. Maguire, E.M.; Pearce, S.W.; Xiao, Q. Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. *Vasc. Pharmacol.* 2019, 112, 54–71. [CrossRef] [PubMed]
30. Getz, G.S.; Krishack, P.A.; Reardon, C.A. Serum amyloid A and atherosclerosis. *Curr. Opin. Lipidol.* 2016, 27, 531–535. [CrossRef] [PubMed]
31. Shridas, P.; Tannock, L.R. Role of serum amyloid A in atherosclerosis. *Curr. Opin. Lipidol.* 2019, 30, 320–325. [CrossRef]
32. Kreuzer, M.; Kreisheimer, M.; Kandel, M.; Schmelzer, M.; Tschense, A.; Grosche, B. Mortality from cardiovascular diseases in the German uranium miners cohort study, 1946–1998. *Radiat. Environ. Biophys.* 2006, 45, 159–166. [CrossRef]